Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 11, 2002 - Issue 9
Submit an article Journal homepage
132
Views
74
CrossRef citations to date
0
Altmetric
Review

Selenium-based pharmacological agents: an update

Sheldon W May School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
Pages 1261-1269 | Published online: 24 Feb 2005

Bibliography

  • WALTER R, SCHWARTZ IL, ROY J: Can selenoamino acids act as reversible biological antioxidants? Ann. NY Acad. Sci. (1972) 192:175–180.
  • LEIBOVITZ B, HU M, TAPPEL AL: Dietary Supplements of vitamin E, b-carotene, coenzyme Q10, and selenium protect tissues against lipid peroxidation in rat tissue slices. Num (1990) 120:97–104.
  • CALD WELL KA, TAPPEL AL: Reactions of seleno- and sulfoamino acids with hydroperwddes. Biochemistry (1964) 3:1643–1647.
  • OLCOTT HS, BROWN WD, VAN DER VEEN J: Selenomethionine as an antioxidant. Nature (1961) 191:1201–1202.
  • COMBS G, COMBS S: The role of selenium M nutrition. Academic Press, N.Y. (1986).
  • MEDINA D: Mechanisms of selenium inhibition of tumorigenesis.j Am. Coll. Toxicol (1986) 5:21–27.
  • IP C: Lessons from basic research in selenium and cancer prevention. Num. (1998) 128:1845–1854.
  • VERNIE LN: Selenium in carcinogenesis. Biochim. Biophys. Acta (1984) 738:203–217.
  • SCHRAUZER GN: Anticarcinogenic effects of selenium. Cell. Ma Life Sci. (2000) 57:1864–1873.
  • CLARK LC, COMBS GE JR, TURNBULL BW et al.: Effect of selenium Supplementation for cancer prevention in patients with carcinoma of the skin. Am. Med. Assoc. (1996) 276:1957–1963.
  • ••This paper remains a landmark account of a long-term, double-blind, placebo-controlled study carried out in the US, which showed that supplementation with dietary selenium markedly reduced the incidence of prostate, colorectal and lung cancer in humans.
  • YOSHIZAWA K, WILLETT WC, MORRIS SJ et al.: Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer." Natl. Cancer Inst (1998) 90:1219–1224.
  • •This study, which indicates that higher selenium levels are associated with a reduced risk of advanced prostate cancer, has attracted very wide media attention.
  • GANTHER HE: Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredwdn reductase. Carcinogenesis (1999) 20:1657–1666.
  • REDMAN C, SCOTT JA, BAINES AT et al.: Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett. (1998) 125:103–110.
  • HUTTUNEN JK: Selenium and cardiovascular diseases-an update. Biomed. Environ. Sci. (1997) 10:220–226.
  • KOSE K, DOGAN P, KARDAS Y et al: Plasma selenium levels in rheumatoid arthritis. Biol. Trace Elem. Res. (1996) 53:51–56.
  • PARNHAM MJ, GRAF E: Seleno-organic compounds and the therapy of hydroperwdde-linked pathological conditions. Biochem. Pharmacol (1987) 36:3095–3102.
  • FOX JM: Selenium: Nutritional implicationsand prospects for therapeutic medicine. Methods Find. Exp. Clin. Pharmacol (1992) 14:275–287.
  • BAUM MK, SHOR-POSNER G, LAI S et al.: High risk of HIV-related mortality is associated with selenium deficiency.' Aaiun: Immune Defic. Syndr: Hum. Retrovirol (1997) 15:370–374.
  • SUBCOMMITTEE ON THE TENTH EDITION OF THE RDA'S, FOOD AND NUTRITION BOARD, COMMISSION ON LIFE SCIENCES, NATIONAL RESEARCH COUNCIL: Recommended Dietary Allowances, 10th edn, National Academy Press, Washington DC, USA. (1989).
  • NATIONAL ACADEMIES OFFICE OF NEWS AND PUBLIC INFORMATION, INSTITUTE OF MEDICINE: Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium and Carotenoids. April 10 (2000).
  • MAY SW: Selenium-based drug design: rationale and therapeutic potential. Expert Opin. Investig. Drugs (1999) 8:1017–1030.
  • LEVANDER OA, BECK MA: Interacting Nutritional and infectious etiologies of Keshan disease. Insights from coxsackie virus B-induced myocarditis in mice deficient in selenium or vitamin E. Biol. Trace Elem. Res. (1997) 56:5–21.
  • BECK MA: Rapid genomic evolution of a non-virulent coxsackievirus B3 in selenium-deficient mice. Biomed. Environ. Sci. (US) (1997) 10:307–315.
  • BECK MA, SHI Q, MORRIS VC et al: Rapid genomic evolution of a non-virulent coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates. Nat. Med. (1995) 1:433–436.
  • ••In this remarkable paper, Beck et al.demonstrated that a non-virulent strain of coxsackievirus mutates in selenium-deficient mice to produce a single genetic variant of the virus, which is now virulent.
  • SHAMBERGER RJ, FROST DV: Possible protective effect of selenium against human cancer. Can. Med. Assoc. (1969) 100:682.
  • SCHRAUZER GN, THEAD WJ: Interpretation of the methylene blue reduction test of human plasma and the possible cancer protecting effect of selenium. Experientia (1971) 27:1069–1071.
  • CLARK LC, CANTOR KP, ALLAWAY WH: Selenium in forage crops and cancer mortality in US counties. Arch. Environ. Health (1991) 46:37–42.
  • YANG GQ, XIA WI: Studies on human dietary requirements and safe range of dietary intakes of selenium in China and their application in the prevention of related endemic diseases. Biomed. Environ. Sci. (1995) 8:187–201.
  • PATTERSON BH, LEVANDER OA: Naturally occurring selenium compounds in cancer chemoprevention trials: a workshop summary. Cancer Epidemiol. Biomarkers Prey. (1997) 6:63–69.
  • TAN J, ZHU W, WANG W et al: Seleniumin soil and endemic diseases in China. Science Total Environ. (2002) 284:227–235.
  • MAY SW, HERMAN HH, ROBERTS SF et atAscorbate depletion as a consequence of product recycling during dopamine b-monooxygenase catalyzed selenwddation. Biochemistry (1987) 26:1626–1632.
  • MAY SW, WIMALASENA K, HERMAN HH et al.: Novel antihypertensives targeted at dopamine b-monooxygenase: turnover-dependent cofactor depletion by phenyl aminoethyl selenide. Med Chem (1988) 31:1066–1068.
  • WIMALASENA K, HERMAN HH, MAY SW: Effects of dopamine b-monooxygenase substrate analogs on ascorbate levels and norepinephrine synthesis in adrenal chromaffin granule ghosts. j. Biol. Chem. (1989) 264:124–130.
  • HERMAN HH, WIMALASENA K, FOWLER LC et al.: Demonstration of the ascorbate dependence of membrane-bound dopamine b-monooxygenase in adrenal chromaffin granule ghosts. j. Biol. Chem. (1988) 263:666–672.
  • POLLOCK SH, HERMAN HH, FOWLER LC et al.: Demonstration of the antihypertensive activity of pheny1-2-aminoethyl selenide. I Pharm. Exp. Therap. (1988) 246:227–234.
  • MAY SW, WANG L, GILL MM et al.: Anorally active selenium-based antihypertensive agent with restricted CNS permeability. Pharm. Exp. Therap. (1997) 283:470–477.
  • •This paper, from the author's laboratory, describes the first orally-active selenium-based antihypertensive compound ever reported. Rational biochemical design, as well as inductively coupled plasma/mass spectroscopy and operant behaviour analyses, were utilised to develop a selenium-based compound which exhibits both oral activity and restricted CNS permeability.
  • OVERCAST JD, ENSLEY AE, BUCCAFUSCO CJ et atEvaluation of Cardiovascular Parameters of a Selenium-Based Antihypertensive Using Pulsed Doppler Ultrasound. Cardiovasc. Pharmacol. (2001) 38:337–346.
  • PARNHAM MJ: The pharmaceutical potential of selenium. Pharmaceut News (1996) 3:7–10.
  • YAMAGUCHI T, SANO K, TAKAKURA K et al.: Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Stroke (1998) 29:12–17.
  • KONO H, ARTEEL GE, RUSYN I, SIES H, THURMAN RG: Ebselen prevents early alcohol-induced liver injury in rats. Free Rad. Biol. Med. (2001) 30:403–411.
  • MOUSSAOUI S, OBINU MC, DANIEL N et al.: The Antioxidant Ebselen Prevents Neurotoxicity and Clinical Symptoms in a Primate Model of Parkinson's disease. Exp. Neurol. (2000) 166:235–245.
  • HSIEH HS, GANTHER HE: Acid-volatileselenium formation catalyzed by glutathione reductase. Biochemistry (1975) 14:1632–1636.
  • GANTHER HE: Selenotrisulfides: Formation by the reaction of thiols with selenious acid. Biochemistry (1968) 7:2898–2905.
  • LANFEAR J, FLEMING J, WU L, WEBSTER G, HARRISON PR: The selenium metabolite selenodiglutathione induces p53 and apoptosis: relevance to the chemopreventive effects of selenium? Carcinogenesis (1994) 15:1387–1392.
  • IP C, GANTHER HE: Comparison of selenium and sulfur analogs in cancer prevention. Carcinogenesis (1992) 13:1167–1170.
  • REN X, BJORNSTEDT M, SHEN B, ERICSON ML, HOLMGREN A: Mutagenesis of structural half-cystine residues in human thioredoxin and effects on the regulation of activity by selenodiglutathione. Biochemistry (1993) 32:9701–9708.
  • SPYROU G, BJORNSTEDT M, KUMAR S, HOLMGREN A: AP-1 DNA-binding activity is inhibited by selenite and selenodiglutathione. FEBS Lett. (1995) 368:59–63.
  • BURKE KE, COMBS GE GROSS EG, BHUYAN KC, ABU-LIBDEH H: The effects of topical and oral L-selenomethionine on pigmentation and skin cancer induced by ultraviolet irradiation. Nutr. Cancer (1992) 17:123–137.
  • REDMAN C, SCOTT JA, BAINES AT et al.: Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett. (1998) 125:103–110.
  • COMBS GE GRAY WP: ChemopreventiveAgents: Selenium. Pharmacol. Therap. (1998) 79:179–192.
  • COMBS GF: Chemopreventive mechanisms of selenium. Med. KIM. (Germany) (1999) 94 (Suppl. III):18–24.
  • FRENKEL GD, CAFFREY PB: A prevention strategy for circumventing drug resistance in cancer chemotherapy. Curr. Pharmacem. Design (2001) 7:1595–1614.
  • ••This paper reports that two seleniumcompounds reduce the induction of resistance by ovarian cancer cells or xenografts to the chemotherapeutic agents melphalan or cisplatin. This is important, since the development of drug resistance is a major reason for the failure of a number of chemotherapeutic agents.
  • VADGAMA JV, WU Y, SHEN D, HSIA S, BLOCK J: Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells. Anti-Cancer Res. (2000) 20:1391–1414.
  • WIMALASENA K, MAY, SW: Ascorbic acidmediated N-dealkylation and N-deoxygenation of N,N-dimethylaniline N-oxide, J. Am. Chem. Soc. (1995) 117:2381–2386.
  • TAMURA T; STADTMAN TC: A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredwdn reductase activity. Proc. Natl. Acad. Sci. USA (1996) 93:1006–1011.
  • ARTEEL GE; SIES H: The biochemistry of selenium and the glutathione system. Envir: Toxicol. Pharmacol. (2001) 10:153–158.
  • AMES BN, SHIGENAGA MK, HAGEN TM: Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Nati Acad. Sci. USA (1993) 90:7915–7922.
  • WOZNICHAK MM, OVERCAST JD, ROBERTSON K, NEUMANN HM, MAY SW: Reaction of phenylaminoethyl selenides with peroxynitrite and hydrogen peroxide. Arch. Biochem. Biophys. (2000) 379:314–320.
  • BJORNSTEDT M, KUMAR S, BJORKHEM L SPYROU G, HOLMGREN A: Selenium and the thioredwdn and glutaredwdn systems. Biomed. Environ. Sci. (1997) 10:271–279.
  • POWIS G, OBLONG JE, GASDASKA PY et al.: The thioredoxin/thioredoxin reductase redox system and control of cell growth. °owl Res. (1994) 6:539–544.
  • BIGUET C, WAKASUGI N, MISHAL Z: Thioredoxin increases the proliferation of human B-cell lines through a protein kinase C-dependent mechanism. j. Biol. Chem. (1994) 269:28865–28870.
  • GASDASKA JR, BERGGREN M, POWIS G: Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ. (1995) 6:1643–1650.
  • ENGMAN L, KANDA T, GALLEGOS A, WILLIAMS R, POWIS G: Water-soluble organotellurium compounds inhibit thioredoxin reductase and the growth of human cancer cells. Anti Cancer Drug Design (2001) 15:323–330.
  • ENGMAN L, COTGREAVE I, ANGULO M et al.: Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents. Anti Cancer Res. (1997) 17:4599–4605.
  • GROMER S, ARSCOTT LD, WILLIAMS CH Jr et al.: Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds.j Biol. Chem. (1998) 273:20096–20101.
  • SMITH AD, GUIDRY CA, MORRIS, VC, LEVANDER OA: Aurothioglucose inhibits murine thioredoxin reductase activity in vivo. J. Nutrition (1999) 129:194–198.
  • YALOWITZ JA, PANKIEWICZ K, PATTERSON SE, JAYARAM HN: Cytotoxicity and cellular differentiation activity of methylenebis(phosphonate) analogs of tiazofurin and mycophenolic acid adenine dinucleotide in human cancer cell lines. Cancer Lett. (2002) 181:31–38.
  • GHAREHBAGHI K, GRUNBERGER W, JAYARAM HN: Studies on the Mechanism of Action of Benzamide Riboside A Novel Inhibitor of IMP Dehydrogenase. Current Med. Chem (2002) 9:743–748.
  • CAO TH, COONEY RA, WOZNICHAK MM, MAY SW, BROWNER RF:Speciation and Identification of Organo-Selenium Metabolites in Human Urine Using Inductively Coupled Plasma/Mass Spectrometry and Tandem Mass Spectrometry. Analytical Chem. (2001) 73:2898–2902.
  • ••This groundbreaking paper represents the first report that the selenium metabolites selenomethionine and selenocystarnine are actually formed in humans. The unequivocal mass spectral structural data reported make this a model for future investigations of selenium metabolites.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.